San Francisco, CA – September 22, 2025 – VeriSIM Life, a leading innovator in AI-driven drug development and translational intelligence, is proud to announce that it has been shortlisted as a finalist in the prestigious 2025 Scrip Awards, under the Innovation Award category.
The Scrip Awards, now in their 21st year, celebrate the very best in global biopharmaceutical innovation and achievement. Making the shortlist for the Innovation Award underscores VeriSIM Life’s pioneering work in leveraging AI-powered biosimulation and advanced predictive modeling to reduce reliance on animal testing, accelerate R&D decision-making, and increase the probability of success for new medicines.
“We are honored to be recognized by the Scrip Awards for innovation that is reshaping how life-saving therapies are developed,” said Dr. Jo Varshney, Founder and CEO of VeriSIM Life. “This recognition is not only a testament to the transformative potential of our BIOiSIM® platform but also to the dedication of our team and partners who share our vision of a smarter, safer, and more ethical path to drug discovery.”
This recognition as a Scrip Awards finalist sets VeriSIM Life apart as a true trailblazer in the biopharmaceutical space, validating the disruptive power of its platform and reinforcing its leadership in driving a more predictive, efficient, and humane model for drug development.
The winners of the 2025 Scrip Awards will be announced on Thursday, December 11, 2025, at the London Hilton Park Lane during the Awards presentation, dinner, and networking evening.
About VeriSIM Life
VeriSIM Life is transforming drug development through its proprietary AI-powered platform, BIOiSIM®. This advanced computational engine simulates human and animal biology to better predict the clinical success of drug candidates in early development. By reducing unnecessary testing and streamlining decision-making, BIOiSIM® drastically improves capital efficiency and reduces time to market for new therapies. To learn more, visit www.verisimlife.com.
AtlasGEN Novel Drug Designer efficiently identifies new molecules based on favorable chemical properties and simultaneously evaluates them for clinical safety and effectiveness based on biology using VeriSIM Life’s groundbreaking Translational Index™ technology.
Iterative ranking of target engaging hits by their Translational Index values reduces the time and cost associated with other computational hit discovery approaches, while compressing the hit-to-lead refinement and optimization process by pre-validating hits for translatability. This unique integration dramatically reduces the number of compounds to evaluate in subsequent experimental research.
The ability to generate target engaging compound hits depends largely on the size of the molecular search library. The AtlasGEN search space is supported by more than 1 trillion compounds. Generative AI and deep learning techniques deliver unprecedented discovery capability.
AtlasGEN accurately predicts protein-lygand binding affinity by combining geometric conformer analysis with machine learning based on experimental data 72% more efficiently than molecular docking-based approaches.
.png)
